Shi Xiang, Du Ting Ting, Zhang Zhihui, Liu Xiaoyu, Yang Ying, Xue Nina, Jiao Xiaozhen, Chen Xiaoguang, Xie Ping
State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China; State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, Jiangsu 210096, China.
State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Bioorg Chem. 2022 Oct;127:106015. doi: 10.1016/j.bioorg.2022.106015. Epub 2022 Jul 10.
Isocryptotanshinone (ICTS), a natural product with potential signal transducer and activator of transcription-3 (STAT3) signaling pathway inhibitory activity, shows significant inhibitory activity against several tumors. In this study, a series of ICTS derivatives and simplified analogs containing a 1, 4-naphthoquinone core was designed, synthesized, and evaluated. The results demonstrated that most target compounds were potent STAT3 signaling pathway inhibitors based on their mechanism of inhibition of STAT3 phosphorylation. Moreover, based on the obtained data, the structure-activity relationship (SAR) was rationally deduced. Simultaneously, molecular docking of the compound 16r suggested its possible interaction mode with STAT3. To further verify anticancer activity, all target compounds were tested using HCT116, HepG, MCF-7, A549, and U251 cell lines. Interestingly, compared with different tumor cell lines, the HCT-116 cell line was determined to be the most sensitive. Furthermore, compounds 21e, 16r, 28a, and 16e showed a dose-dependent inhibition of the growth of HCT116 cells. Thus, the SAR of ICTS derivatives and its simplified analogs was determined, and some of them were discovered to be potential anticancer candidates owing to their ability to inhibit the STAT3 signaling pathway.
异隐丹参酮(ICTS)是一种具有潜在信号转导子和转录激活因子3(STAT3)信号通路抑制活性的天然产物,对多种肿瘤显示出显著的抑制活性。在本研究中,设计、合成并评估了一系列含有1,4-萘醌核心的ICTS衍生物和简化类似物。结果表明,基于其对STAT3磷酸化的抑制机制,大多数目标化合物是有效的STAT3信号通路抑制剂。此外,根据获得的数据,合理推导了构效关系(SAR)。同时,化合物16r的分子对接表明了其与STAT3可能的相互作用模式。为进一步验证抗癌活性,使用HCT116、HepG、MCF-7、A549和U251细胞系对所有目标化合物进行了测试。有趣的是,与不同肿瘤细胞系相比,HCT-116细胞系被确定为最敏感。此外,化合物21e、16r、28a和16e对HCT116细胞的生长显示出剂量依赖性抑制。因此,确定了ICTS衍生物及其简化类似物的构效关系,其中一些由于能够抑制STAT3信号通路而被发现是潜在的抗癌候选物。